Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) on Wednesday, citing the potential of its epilepsy franchise. Analyst Rudy Li writes, “Epilepsy remains one of our ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...

Praxis Precision Medicines, Inc. announced significant advancements in its clinical portfolio, highlighting three late-stage assets poised for potential blockbuster status and the expectation of four ...

Praxis Precision Medicines, Inc. announced significant progress in its clinical pipeline, projecting six major study readouts across four programs in the next 12 months. The company plans to initiate ...

Long questions, similar answer choices, and strict pacing can make familiar material feel harder. The Praxis is not impossible, but it is not a test you want to walk into unprepared. As a test prep ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Praxis Precision Medicines (PRAX) shares shot skyward Friday after the company stopped an epilepsy study early due to strong effectiveness. The company says it will present the results from its study ...

Praxis Precision Medicines Inc. PRAX on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures. The company said the overall outcome fell short of ...